Cellarity, a clinical-stage, biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced acceptance of two oral presentations on ...
Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...
Utilizes human LINE-1 machinery to drive programmable, site-specific integration of multi-kb payloads, without ...
Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis ...
Type 1 diabetes (T1D) is a chronic autoimmune disease that results from the destruction of insulin-producing β-cells in the ...
Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has ...
Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended September 30, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback